

STRATEGIC PARTNERSHIP WITH INDIA

BOARD MEETING

Homero Hernandez

30 November – 2 December 2021

Virtual Meeting



Reach every child

www.gavi.org

Modest investments can save thousands of lives and catalyse long-term impact

Strategic focus and objectives

Zero-dose & missed communities

- Reduce # of zero-dose children **in line with Immunisation Agenda 2030 (IA2030) goals (-30% by 2026)** through targeted **sub-national strategies**

Equity-focused vaccine introductions

- **Human papillomavirus (HPV):** avert ~66'000 future deaths
- **Typhoid conjugate vaccine (TCV):** avert ~52'000 future deaths

Gavi support


US\$ 119 million
Health systems strengthening (HSS)
US\$ 10 million
Technical Assistance (TA/HSS)

US\$ 116 million
New & underused vaccine support (NVS)
US\$ 6 million
TCV surveillance (HSS)

- Select investments in national and subnational **institutions**
- +** Continued engagement on **vaccine and cold chain equipment market shaping**
- Alignment with separate **COVID-19 vaccine support** through COVAX

Strong geographic concentration of **zero-dose** children enables **targeted subnational strategies**

Potential focus states with high # of zero-dose children



Catalytic investments to sustainably reach zero-dose & under-immunised children

What?

- Stronger focus on **demand and data**
- **Selected supply-side** interventions where Gavi funding can bring **innovative approaches to scale**
- Focus on **sustainable** improvements in RI systems

How?

- Exploring multisectoral **partnerships beyond immunization**, increasing the role of **community-based and civil society organisations** (CSOs), esp. those focused on demand issues as well as private sector filling capacity gaps
- **Capacity building** in national institutions with the aim of ensuring long-term sustainability and programme performance

Introduction of HPV and Typhoid vaccines will boost equity in immunisation in India

- Full Government **commitment** to introduce both TCV and HPV
- Global **supply constraints** and market shaping considerations reflected in strategic approach
- Some **flexibility** to be retained within the vaccine funding envelope given the uncertain environment

	HPV	TCV
Approach	<ul style="list-style-type: none">▪ Gradual introduction in 2024▪ Supply availability influencing intro timing and scale	<ul style="list-style-type: none">▪ Set-up of sentinel surveillance sites in 2023-2025▪ Approach to be informed by NITAG recommendation
Impact	<ul style="list-style-type: none">▪ ~5.8 million girls immunised▪ ~66,000 lives saved	<ul style="list-style-type: none">▪ ~50 million people immunised▪ ~52,000 lives saved

Recommendation

The Gavi Alliance Programme and Policy Committee **recommends** to the Gavi Alliance Board that it:

- a) **Approve** the strategic approach set forth in Annex A to Doc 10 to continue Gavi's strategic partnership with India for five years (2022-2026); and
- b) **Approve** the associated investment of US\$ 250 million for 2022-2026, of which US\$ 199 million will be implemented in Gavi 5.0 (2022-2025).



Reach every child

www.gavi.org